Companies › Ocugenix
1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OCU-10-C-110 for Injection | – | Phase 1 | Neovascular Age-related Macular Degeneration (nAMD) | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05904691 | OCU-10-C-110 for Injection | Phase 1 | Neovascular Age-related Macular Degeneration (nAMD) | Ophthalmology | Nov 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.